MedTrace Logo

Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum

NCT03360760 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-08-28

No results posted yet for this study

Summary

To study the effect of the timing of surgery on outcome of patients with nonmetastatic osteosarcoma of pelvis and sacrum.

Conditions

  • Osteosarcoma of Pelvis

Interventions

DRUG

Doxorubicin

60mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH

DRUG

Cisplatin

100mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH

DRUG

Methotrexate

High dose of methotrexate (8-12g/m\^2), in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH

DRUG

Ifosfamide

12g/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH

PROCEDURE

definitive surgery

Including limb-sparing procedure and amputation

OTHER

pre surgical chemotherapy

chemotherapy that given before definitive surgery

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Wei Guo · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2020-02-29
Completion
2025-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03360760 on ClinicalTrials.gov